| Followers | 21 |
| Posts | 2241 |
| Boards Moderated | 0 |
| Alias Born | 08/11/2021 |
Wednesday, December 18, 2024 12:56:33 PM
How do you explain the present price action?
Recent MTVA News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 12:45:31 PM
- MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity • PR Newswire (US) • 04/10/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/07/2026 08:01:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/07/2026 04:15:05 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/03/2026 08:03:37 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/03/2026 08:01:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:30:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 12:45:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:31:20 PM
- MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/26/2026 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2026 12:05:20 PM
- MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control • PR Newswire (US) • 03/18/2026 12:00:00 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 • PR Newswire (US) • 03/12/2026 01:01:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 • PR Newswire (US) • 02/13/2026 01:31:00 PM
- MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel • PR Newswire (US) • 02/04/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/27/2026 09:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 09:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 09:05:21 PM
- MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option • PR Newswire (US) • 01/16/2026 09:01:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/16/2026 01:36:51 PM
- MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering • PR Newswire (US) • 01/15/2026 02:32:00 PM
- Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] • Edgar (US Regulatory) • 01/15/2026 02:12:56 PM
